Abstract
In late 2012, regorafenib (Stivarga), a novel oral multikinase inhibitor, was approved by the FDA for certain previously treated patients with metastatic colorectal cancer. Even more recently, regorafenib received another approval for use in select patients with refractory gastrointestinal stromal tumor. Read about key clinical trials, mechanism of action, adverse effects, and dosing and administration guidelines associated with this generally well-tolerated agent.
